Miglietta, F., Griguolo, G., Bottosso, M., Giarratano, T., Mele, M. L., Fassan, M., . . . Dieci, M. V. (2022). HER2-low-positive breast cancer: Evolution from primary tumor to residual disease after neoadjuvant treatment. Nature Portfolio.
Citación estilo ChicagoMiglietta, Federica, et al. HER2-low-positive Breast Cancer: Evolution From Primary Tumor to Residual Disease After Neoadjuvant Treatment. Nature Portfolio, 2022.
Cita MLAMiglietta, Federica, et al. HER2-low-positive Breast Cancer: Evolution From Primary Tumor to Residual Disease After Neoadjuvant Treatment. Nature Portfolio, 2022.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.